Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Barinthus Biotherapeutics PLC - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
BRNS
Nasdaq
8731
https://www.barinthusbio.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Barinthus Biotherapeutics PLC
Increases to CEO Compensation Might Be Put On Hold For Now at Barinthus Biotherapeutics plc (NASDAQ:BRNS)
- May 4th, 2024 12:23 pm
Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer
- May 1st, 2024 11:00 am
Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections
- Apr 18th, 2024 8:10 pm
Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments
- Mar 20th, 2024 12:15 pm
Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones
- Jan 5th, 2024 9:01 pm
New partnership aims to advance vaccine against MERS coronavirus
- Dec 21st, 2023 12:31 pm
Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD
- Nov 9th, 2023 9:24 pm
Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver MeetingĀ®
- Nov 9th, 2023 9:01 pm
Barinthus Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
- Nov 9th, 2023 9:01 pm
Scroll